Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation

Yen-Fu Chen; Susan Jowett; Pelham Barton; Kinga Malottki; Christopher Hyde; S Gibbs; J Pepke-Zaba; Anne Fry-Smith; J Roberts; David Moore

doi:10.3310/hta13490

Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation

Yen-Fu Chen
, Susan Jowett
, Pelham Barton
, Kinga Malottki
, Christopher Hyde
, S Gibbs
, J Pepke-Zaba
, Anne Fry-Smith
, J Roberts
, David Moore

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Original language	English
Pages (from-to)	1-320
Journal	Health Technology Assessment
Volume	13
Issue number	49
DOIs	https://doi.org/10.3310/hta13490
Publication status	Published - 1 Jan 2010

Access to Document

10.3310/hta13490

Cite this

Chen, Y.-F., Jowett, S., Barton, P., Malottki, K., Hyde, C., Gibbs, S., Pepke-Zaba, J., Fry-Smith, A., Roberts, J., & Moore, D. (2010). Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation. Health Technology Assessment, 13(49), 1-320. https://doi.org/10.3310/hta13490

@article{5e119f488f0243019f014bd13bd29636,

title = "Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation",

author = "Yen-Fu Chen and Susan Jowett and Pelham Barton and Kinga Malottki and Christopher Hyde and S Gibbs and J Pepke-Zaba and Anne Fry-Smith and J Roberts and David Moore",

year = "2010",

month = jan,

day = "1",

doi = "10.3310/hta13490",

language = "English",

volume = "13",

pages = "1--320",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NIHR Health Technology Assessment Programme",

number = "49",

}

Chen, Y-F , Jowett, S, Barton, P, Malottki, K, Hyde, C, Gibbs, S, Pepke-Zaba, J, Fry-Smith, A, Roberts, J & Moore, D 2010, 'Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation', Health Technology Assessment, vol. 13, no. 49, pp. 1-320. https://doi.org/10.3310/hta13490

Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation. / Chen, Yen-Fu ; Jowett, Susan; Barton, Pelham et al.
In: Health Technology Assessment, Vol. 13, No. 49, 01.01.2010, p. 1-320.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension in adults: a systematic review and economic evaluation

AU - Chen, Yen-Fu

AU - Jowett, Susan

AU - Barton, Pelham

AU - Malottki, Kinga

AU - Hyde, Christopher

AU - Gibbs, S

AU - Pepke-Zaba, J

AU - Fry-Smith, Anne

AU - Roberts, J

AU - Moore, David

PY - 2010/1/1

Y1 - 2010/1/1

U2 - 10.3310/hta13490

DO - 10.3310/hta13490

M3 - Article

SN - 2046-4924

VL - 13

SP - 1

EP - 320

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 49

ER -